Parse Biosciences and Integra Automated Evercode Single-Cell Bundle
Parse Biosciences and lab automation firm Integra have released product bundles to support an automated version of Parse's Evercode single-cell RNA-sequencing technology using Integra's Assist Plus pipetting robot.
The workflow uses Integra's D-One single-channel pipetting module and an eight-channel Viaflo electronic pipette to enable Parse customers to increase throughput and reduce errors in sample preparation. It may reduce hands-on time by up to 75 percent and manual pipetting steps by up to 85 percent. The bundle is available with either two Evercode WT kits or one Evercode WT kit and one Evercode WT Mega kit. An Evercode automation "starter" kit for the Integra Assist Plus is also available.
PCR Biosystems Clara and Air-Dryable Inhibitor-Tolerant PCR Mixes
London-based PCR Biosystems has launched its Clara and Air-Dryable Inhibitor-Tolerant PCR mixes. The Clara Inhibitor-Tolerant Probe Mix and Probe 1-Step Mix are concentrated 4X mixes that contain all the essential components for probe-based qPCR or RT-qPCR, including hot start Taq DNA polymerase, dNTPs, magnesium, and, for the 1-step mix, a modified version of UltraScript reverse transcriptase with advanced RNase inhibitor. The single-tube format simplifies setup and requires only the addition of primers, probes, and sample, the company said.
The Air-Dryable Inhibitor-Tolerant Probe Mix and Probe 1-Step Mix enable simple, fast, and low-cost dried assays. An optimal blend of excipients ensures reliable drying without loss of activity and assays can be dried with a standard laboratory oven in as little as 80 minutes, PCR Biosystems said.
Eclipsebio eMERGE Platform
Eclipse Bioinnovations (Eclipsebio), a San Diego-based RNA genomics company, has launched its eMERGE platform for the characterization and optimization of RNA-based therapeutic products, including vaccines, protein and gene therapies, and monoclonal antibodies. eMERGE will enable the company's partners to obtain actionable insights into RNA-based drug products by providing detailed measurements of therapeutic translation, stability-influencing structure, RNA substance identity and integrity, and evaluations of LNP and storage effects. The platform can also provide guidance for precise optimizations to improve therapeutic efficacy including identification of optimal sequences for translation and stability, the company said.
For more recently launched products and services, please visit the New Products page on our website.